BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38006840)

  • 41. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
    Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
    BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
    He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
    Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
    Du C; Ni M; Jiang J; Kong F; Zhai R; Lv Y; Hu C; Ying H
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3947-3956. PubMed ID: 34981158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
    Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
    Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
    Tang LQ; Hu DP; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Wen SH; Peng YT; Chen WH; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mai HQ
    PLoS One; 2015; 10(4):e0122965. PubMed ID: 25874450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
    Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
    Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensity-modulated radiotherapy for stage IVA/IVB nasopharyngeal carcinoma: clinical outcomes and patterns of failure in an endemic area in China.
    Zeng L; Tian YM; Sun XM; Huang Y; Chen CY; Han F; Liu S; Lan M; Guan Y; Deng XW; Lu TX
    Strahlenther Onkol; 2014 Oct; 190(11):993-1000. PubMed ID: 24838409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma.
    Lu J; Chen XM; Huang HR; Zhao FP; Wang F; Liu X; Li XP
    Head Neck; 2018 Jun; 40(6):1245-1253. PubMed ID: 29493822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Yao JJ; He XJ; Lawrence WR; Zhang WJ; Kou J; Zhang F; Zhou GQ; Wang SY; Sun Y
    Cell Physiol Biochem; 2018; 48(1):285-292. PubMed ID: 30011397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Hong X; Wang G; Xu G; Shi W; Wang T; Rong Z; Mo C
    Medicine (Baltimore); 2022 Jan; 101(3):e28507. PubMed ID: 35060503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
    Bin Y; Meng Z; Huang LL; Hu XY; Song JM; Xie YT; Kang M; Wang RS
    Radiother Oncol; 2022 Dec; 177():185-190. PubMed ID: 36375560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and Validation of a Prognostic Nomogram Based on Residual Tumor in Patients With Nondisseminated Nasopharyngeal Carcinoma.
    Liao PY; Dong ZY; Huang CT; Tang XR; Liu GD; Zhu-Liu ; Wu DH
    Technol Cancer Res Treat; 2020; 19():1533033820957035. PubMed ID: 32945239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa.
    Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL
    Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
    Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
    Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.